心的外傷後ストレス障害(Post-Traumatic Stress Disorder (PTSD))の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Post-Traumatic Stress Disorder (PTSD) Overview 9
Therapeutics Development 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) – Overview 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) – Comparative Analysis 11
Post-Traumatic Stress Disorder (PTSD) – Therapeutics under Development by Companies 12
Post-Traumatic Stress Disorder (PTSD) – Therapeutics under Investigation by Universities/Institutes 14
Post-Traumatic Stress Disorder (PTSD) – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Post-Traumatic Stress Disorder (PTSD) – Products under Development by Companies 19
Post-Traumatic Stress Disorder (PTSD) – Products under Investigation by Universities/Institutes 21
Post-Traumatic Stress Disorder (PTSD) – Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Azevan Pharmaceuticals, Inc. 23
Catalyst Pharmaceutical Partners, Inc. 24
Humanetics Corporation 25
Intra-Cellular Therapies, Inc. 26
Marinus Pharmaceuticals, Inc. 27
Nanotherapeutics, Inc. 28
Neuralstem, Inc. 29
Neurocrine Biosciences, Inc. 30
NeuroNascent, Inc. 31
Omeros Corporation 32
Otsuka Holdings Co., Ltd. 33
Polleo Pharma Limited 34
Tonix Pharmaceuticals Holding Corp. 35
Vanda Pharmaceuticals Inc. 36
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
7-Keto – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ADX-71743 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brexpiprazole – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CPP-115 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug for Post-Traumatic Stress Disorders – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Drugs to Inhibit FAAH for CNS Disorders – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ganaxolone – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
iloperidone – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ITI-007 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NNI-351 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NSI-189 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NTC-942 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Rycal – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
S-107 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Target GPR151 for CNS Diseases – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule to Target GPR83 for CNS and Immunological Disorders – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules for BED and PTSD – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Post-Traumatic Stress Disorder – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Antagonize TLR-4 for CNS Disorders – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SRX-246 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SRX-251 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
TNX-102 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Vaccine for Post-Traumatic Stress Disorder and Depression – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
verucerfont – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
vigabatrin – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ZL-006 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Post-Traumatic Stress Disorder (PTSD) – Recent Pipeline Updates 86
Post-Traumatic Stress Disorder (PTSD) – Dormant Projects 106
Post-Traumatic Stress Disorder (PTSD) – Discontinued Products 107
Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones 108
Featured News & Press Releases 108
Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 108
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women’s Healthcare Innovation and Leadership Showcase on October 15, 2013 108
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 109
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 109
Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 110
Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 110
May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder 111
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 112
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 112
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 113
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115